STEPS for Autism Spectrum Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Autism Spectrum Disorder+2 More
STEPS - Behavioral
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

The goal of this study is to conduct the first community-based implementation of the STEPS program and test feasibility and preliminary impact. After first working with stakeholders to refine and optimize the program we will launch a Hybrid Type 1 open trial, targeting 25 transition-age youth (TAY) with ASD.

Eligible Conditions
  • Autism Spectrum Disorder
  • Autism Spectrum Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Autism Spectrum Disorder

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Week 14

Week 14
Adult Functioning Scale
Rehabilitation Success

Trial Safety

Safety Progress

1 of 3

Other trials for Autism Spectrum Disorder

Trial Design

1 Treatment Group

STEPS
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: STEPS · No Placebo Group · N/A

STEPS
Behavioral
Experimental Group · 1 Intervention: STEPS · Intervention Types: Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STEPS
2014
N/A
~50

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: week 14

Who is running the clinical trial?

University of Alabama, TuscaloosaLead Sponsor
30 Previous Clinical Trials
6,301 Total Patients Enrolled
1 Trials studying Autism Spectrum Disorder
200 Patients Enrolled for Autism Spectrum Disorder
Susan W WhitePrincipal InvestigatorUniversity of Alabama at Birmingham

Eligibility Criteria

Age < 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
North Carolina100.0%
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%